跳至主要内容
临床试验/DRKS00007568
DRKS00007568已完成4 期

European Long-acting Antipsychotics in Schizophrenia Trial - EULAST

Foundation European Group for Research in Schizophrenia (EGRIS)0 个研究点目标入组 523 人开始时间: 2015年6月18日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
523

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Diagnosis of schizophrenia as defined by DSM-IV-R( Diagnostic and Statistical Manual) as determined by the M.I.N.I.plus
  • Age 18 or older.
  • The first psychosis occurred at least six months and no more than 7 years ago.
  • If patients are using an antipsychotic drug, a medication switch is currently under consideration.
  • Capable of providing written informed consent

排除标准

  • Intolerance / hypersensitivity to one of the drugs (including active substances, metabolites and excipients) in this study including oral risperidone, paliperidone and aripiprazole.
  • Pregnancy or lactation.
  • Patients who are currently using clozapine.
  • Patients who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate.
  • Patients with a documented history of non-response and/or intolerance to any of the study medications.
  • Forensic patients.
  • Patients who have been treated with an investigational drug within 30 days prior to screening.

研究者

发起方
Foundation European Group for Research in Schizophrenia (EGRIS)

相似试验

European Long-acting Antipsychotics in Schizophrenia... | 临床试验